Newbury Pharmaceuticals is strengthening its oncology portfolio
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the oncology portfolio with the addition of Lapatinib. Lapatinib is a targeted cancer drug, also known by its brand name Tyverb®, that is used to treat certain type of breast cancers, whose tumours overexpress HER2.
“Lapatinib is a terrific supplement to the existing high-value product portfolio and we are proud to further strengthen our commitment within oncology” says Mr Lars Minor CEO of Newbury
Newbury currently has eleven (11) products within oncology and providing treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer, NSCLC and thyroid cancer).
Regulatory filling will take place during the next few years, and we aim to be among the first to launch many of these medicines in Scandinavia where the total annual value of this market is estimated to be 400 MEUR according to DLMI Nordic Pharma Insights.
”Newbury is a start-up with high ambitions and we are rapidly growing our portfolio within our focus areas of oncology, rare diseases and neurology. We want to be known to make a difference within these therapeutic areas” says Karl Karlsson Founder & Chairman
